Journal Mobile Options
Table of Contents
Vol. 146, No. 1, 2008
Issue release date: April 2008
Int Arch Allergy Immunol 2008;146:76–84
(DOI:10.1159/000112506)

A Randomized Controlled Trial of Sublingual Immunotherapy for Japanese Cedar Pollinosis

Horiguchi S. · Okamoto Y. · Yonekura S. · Okawa T. · Yamamoto H. · Kunii N. · Sakurai D. · Fujimura T. · Nakazawa K. · Yasueda H.
aDepartment of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University and bDepartment of Pharmacy, Chiba University Hospital, Chiba, and cClinical Research Center, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Japanese cedar pollen represents an important and unique allergen. Sublingual immunotherapy (SLIT) has been suggested to be a highly effective route of desensitization against a variety of allergens. However, little information is available about its use in cedar pollen allergy. Methods: A blinded randomized, placebo-controlled trial employing SLIT for cedar pollinosis was conducted over a period of 6 months. Sixty-seven subjects were enrolled and the symptom scores during the pollen season were evaluated by a symptom diary, measurement of cedar-specific IgE and IgG4, and determination of Cry j-specific Th2 clones before SLIT and before and after the pollen season. Results: No major adverse effects were observed in either group. The serum-specific IgG4 activity increased significantly after SLIT in the active group. The active group also exhibited significantly lower symptom scores compared to the placebo. The specific Th2 clone sizes were not significantly different between the groups before the pollen season. However, an increase in the clone size was observed after the pollen season in the placebo group, but not in the active group. Conclusion: Use of SLIT for Japanese cedar pollinosis was found to be safe and associated with an increase in cedar-specific IgG4 levels. Such therapy inhibited the increase in Cry j-specific Th2 clone size induced by pollen exposure. Finally, use of SLIT resulted in significant improvement of the clinical symptoms of cedar pollinosis in this patient population. These observations suggest that SLIT may offer another safe approach to the management of cedar pollinosis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bousquet J, van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:s147–s334.
  2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225–1232.
  3. Okuda M: Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288–296.
  4. Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A: Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol 2005;136:365–371.
  5. Ito Y, Takahashi Y, Fujita T, Fukuyama S: Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination. Auris Nasus Larynx 1997;24:163–170.
  6. Ito H, Nishimura J, Suzuki M, Mamiya S, Sato K, Takagi I, Baba S: Specific IgE to Japanese cypress (Chamaecyparis obtusa) in patients with nasal allergy. Ann Allergy Asthma Immunol 1995;74:299–303.
  7. Katelaris CH, Burke TV, Byth K: Spatial variability in the pollen count in Sydney, Australia: can one sampling site accurately reflect the pollen count for a region? Ann Allergy Asthma Immunol 2004;93:131–136.
  8. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D; Immune Tolerance Network Group: Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–1455.
  9. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:1177–1183.
  10. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434–440.
  11. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265–269.
  12. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR: Grass pollen immunotherapy: efficacy and safety during a 4-year follow up study. Allergy 1995;50:405–413.
  13. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M: A double-blind placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489–500.
  14. Okuda M: A long-term follow-up study after discontinuation of immunotherapy for Japanese cedar pollinosis. Arerugi 2006;55:655–661.

    External Resources

  15. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC: Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(suppl 1):47–55.

    External Resources

  16. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021–1035.
  17. Burastero SE: Sublingual immunotherapy for allergic rhinitis: an update. Curr Opin Otolaryngol Head Neck Surg 2006;14:197–201.
  18. Passalacqua G, Lombardi C, Guerra L, Compalati E, Fumagalli F, Canonica GW: Sublingual immunotherapy: no more doubts. Allerg Immunol (Paris) 2005;37:314–320.
  19. Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4–12.
  20. Bousquet J, Demoly P: Specific immunotherapy – an optimistic future. Allergy 2006;61:1155–1158.
  21. Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ: Safety and tolerability of grass pollen tablets in sublingual immunotherapy: a phase-1 study. Allergy 2006;61:1173–1176.
  22. Hirahara K, Tatsuta T, Takatori T, Ohtsuki M, Kirinaka H, Kawaguchi J, Serizawa N,Taniguchi Y, Saito S, Sakaguchi M, Inouye S, Shiraishi A: Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001;108:94–100.
  23. Ohkubo K, Takizawa R, Gotoh M, Okuda M: Experience of specific immunotherapy with standardized Japanese cedar pollen extract. Arerugi 2001;50:520–527.
  24. Yasueda H, Akiyama K, Maeda Y, Hayakawa T, Kaneko F, Hasegawa M, Shida T: An enzyme-linked immunosorbent assay (ELISA) for the quantitation of sugi pollen and Dermatophagoides mite allergens and its application for standardization of allergen extracts. Arerugi 1991;40:1218–1225.
  25. Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4–12.
  26. Okuda M: Grading the severity of allergic rhinitis for treatment strategy and drug study purposes. Curr Allergy Asthma Rep 2001;1:235–241.
  27. Yasueda H, Yui Y, Shimizu T, Shida T: Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria Japonica) pollen. J Allergy Clin Immunol 1983;71:77–86.
  28. Delaunay J, Sasajima H, Okamoto Y, Yokota M: Side-by-side comparison of automatic pollen counters for use in pollen information system. Ann Allergy Asthma Immunol 2007;98:553–558.
  29. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425–432.
  30. Pajno GB, Morabito L, Barberio G: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55:842–849.
  31. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507–514.
  32. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006;61:151–165.
  33. Frati F, Incorvaia C, Marcucci F, Sensi L, Di Cara G, Puccinelli P, Dal Bo S: Dose dependence of efficacy but not of safety in sublingual immunotherapy. Monaldi Arch Chest Dis 2006;65:38–40.
  34. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA: IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205–1214.
  35. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
  36. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006;117:433–442.
  37. Sun JB, Cuburu N, Blomguist M, Li BL, Czerkinsky C, Holmgren J: Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+ CD25+ CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 2006;64:251–259.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50